Recent News

• 06.02.2025 - BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
• 06.02.2025 - BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
• 05.07.2025 - Citizens Life Sciences Conference
• 05.07.2025 - Citizens Life Sciences Conference
• 05.06.2025 - BioAtla First Quarter 2025 Financial Results and Business Highlights Conference Call
• 05.06.2025 - BioAtla First Quarter 2025 Financial Results and Business Highlights Conference Call
• 05.06.2025 - BioAtla First Quarter 2025 Financial Results and Business Highlights Conference Call
• 05.06.2025 - BioAtla First Quarter 2025 Financial Results and Business Highlights Conference Call
• 05.06.2025 - BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
• 05.06.2025 - BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Recent Filings

• 05.20.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.16.2025 - 8-K Current report
• 05.16.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.14.2025 - EFFECT Notice of Effectiveness
• 05.06.2025 - S-3 Registration statement under Securities Act of 1933
• 05.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2025 - EX-99.1 EX-99.1
• 05.06.2025 - 8-K Current report